|
|
|
Orexin
(hypocretin) in Narcolepsy |
 |
Phoenix
Pharmaceuticals, Inc.
The Peptide Elite
www.phoenixpeptide.com
|
|
|
Using Phoenix Pharmaceuticals' Hypocretin-1/Orexin A RIA kit, Nishino,
and co-workershave found that Hypocretin/Orexin- like immunoreactivity
in the cerebrospinal fluid (CSF) from narcolepsy patients is under detectable
levels [1] as compared with normal subjects( <40 ng/ml vs 285ng/ml
).
The hypothalamus is a major regulatory center for autonomic and endocrine
homeostasis, where hypothalamic-specific peptides exert their important
roles by transport to the pituitary, by entering the general circulation,
or by secretion within the central nervous system. Hypocretins/Orexins are
hypothalamic-specific peptides with neuro-excitatory, feeding behavior,
endocrine and cardiovascular function [4,7,8,9,10,11]. Recently, attention
has been focused on their role in sleep regulation [1,2,3,5,6]. Human narcolepsy
may relate to Hypocretin / Orexin deficiency in brain.
Neurons containing Hypocretin are located exclusively in the lateral
hypothalamus and send axons to numerous regions throughout the central nervous
system, including the major nuclei implicated in sleep control. It was reported
that the brain region receiving the densest innervation from orexinergic
nerves is the locus coeruleus, a key modulator of attentional state, where
application of Orexin A increased cell firing of intrinsic noradrenergic
neurons. Orexin A increased arousal and locomotor activity and modulated
neuroendocrine functions [5]. These data suggest that Hypocretins/Orexins
play an important role in orchestrating the sleep-wake cycle.
Narcolepsy is a disabling sleep disorder affecting humans and animals.
It is characterized by daytime sleepiness, cataplexy, and striking transitions
from wakefulness into rapid eye movement (REM) sleep [2]. Lin and co-workers
have found that canine narcolepsy can be caused by disruption of the Hypocretin/Orexin
receptor 2 gene (Hcrtr2) [2]. Homozygous Hypocretin knockout mice showed
a phenotype strikingly similar to that in human narcolepsy patients, as
well as canarc-1 mutant dogs, the only known monogenic model of narcolepsy
[3].
This is the first report that Hypocretin neurotransmission is deficient
in some people with narcolepsy. These results, together with the observation
that hypocretin receptor and peptide gene alterations induce narcolepsy
in animal models, suggest that Hypocretin/Orexin deficiency contributes
to narcolepsy.
- Nishino, S. et al. Hypocretin (Orexin) deficiency in human narcolepsy.
Lancet, 355, 39-40 (2000)
- Lin, L. et al. The sleep disorder canine narcolepsy is caused by a
mutation in the hypocretin (orexin) receptor 2 gene. Cell 98,365-376
(1999)
- Chemelli, R.M., et al. Narcolepsy in Orexin knockout mice: molecular
genetics of sleep regulation. Cell 98, 437-451(1999)
- De Lecea, L. et al. The Hypocretins: hypothalamous-specific peptides
with neuroexcitatory activity. Proc. Nat. Acad. Sci. 95, 322-327 (1998)
- Hagan, J.J. et al. Orexin A activates locus coeruleus cell firing
and increases arousal in the rat. Proc. Nat. Acad. Sci. 96, 10911-10916
(1999)
- Siegel, J.M. Narcolepsy: a key role for Hypocretins (Orexins). Cell
98, 409-412 (1999)
- Samson, W.K., Gosnell, B., Chang, J.K., et al. Cardiovascular regulatory
actions of the Hypocretins in brain. Brain Res. 831,248-253 (1999)
- Kirchgessner, A.L. and Liu, M. Orexin synthesis and response in the
gut. Neuron 1999 Dec;24 (4): 941-51
- Lopez, M. et al. Orexin receptors are expressed in the adrenal medulla
of the rat. Endocrinology 140, 5991-4 (1999)
- Yamamoto, Y. et al, Down regulation of the prepro-orexin gene expression
in genetically obese mice. Brain Res Mol Brain Res. 65,14-22 (1999)
- Antonarakis, S.E. and Mckusick V.A. OMIM *602393 Hypocretin Receptor 2.
| Orexin Preprohormone Sequence Comparison
across Species |
|
| Prepro-Orexin (Human) |
N |
N |
L |
P |
S |
T |
K |
V |
S |
W |
A |
A |
V |
T |
L |
L |
L |
L |
L |
L |
L |
L |
P |
P |
A |
L |
L |
S |
S |
G |
| Prepro-Orexin (Rat) |
N |
N |
L |
P |
S |
T |
K |
V |
P |
W |
A |
A |
V |
T |
L |
L |
L |
L |
L |
L |
L |
- |
P |
P |
A |
L |
L |
S |
P |
L |
| Prepro-Orexin (Mouse) |
N |
N |
F |
P |
S |
T |
K |
V |
P |
W |
A |
A |
V |
T |
L |
L |
L |
L |
L |
L |
L |
- |
P |
P |
A |
L |
L |
S |
P |
L |
| |
Orexin A |
| Prepro-Orexin (Human) |
A |
A |
A |
Q |
P |
L |
P |
D |
C |
C |
R |
Q |
K |
T |
C |
S |
C |
R |
L |
Y |
E |
L |
L |
H |
G |
A |
G |
N |
H |
A |
| Prepro-Orexin (Rat) |
A |
A |
A |
Q |
P |
L |
P |
D |
C |
C |
R |
Q |
K |
T |
C |
S |
C |
R |
L |
Y |
E |
L |
L |
H |
G |
A |
G |
N |
H |
A |
| Prepro-Orexin (Mouse) |
A |
A |
A |
Q |
P |
L |
P |
D |
C |
C |
R |
Q |
K |
T |
C |
S |
C |
R |
L |
Y |
E |
L |
L |
H |
G |
A |
G |
N |
H |
A |
| |
Orexin B |
| Prepro-Orexin (Human) |
A |
G |
I |
L |
T |
L |
G |
K |
R |
R |
S |
G |
P |
P |
G |
L |
Q |
G |
R |
L |
Q |
R |
L |
L |
Q |
A |
S |
G |
N |
H |
| Prepro-Orexin (Rat) |
A |
G |
I |
L |
T |
L |
G |
K |
R |
R |
P |
G |
P |
P |
G |
L |
Q |
G |
R |
L |
Q |
R |
L |
L |
Q |
A |
N |
G |
N |
H |
| Prepro-Orexin (Mouse) |
A |
G |
I |
L |
T |
L |
G |
K |
R |
R |
P |
G |
P |
P |
G |
L |
Q |
G |
R |
L |
Q |
R |
L |
L |
Q |
A |
N |
G |
N |
H |
| |
|
| Prepro-Orexin (Human) |
A |
A |
G |
I |
L |
T |
N |
G |
R |
R |
A |
G |
A |
E |
P |
A |
P |
R |
P |
C |
L |
G |
R |
R |
C |
S |
A |
P |
A |
A |
| Prepro-Orexin (Rat) |
A |
A |
G |
I |
L |
T |
N |
G |
R |
R |
A |
G |
A |
E |
L |
E |
P |
Y |
P |
C |
P |
G |
R |
R |
C |
P |
T |
A |
T |
A |
| Prepro-Orexin (Mouse) |
A |
A |
G |
I |
L |
T |
N |
G |
R |
R |
A |
G |
A |
E |
L |
E |
P |
H |
P |
C |
S |
G |
R |
G |
C |
P |
T |
V |
T |
T |
| |
|
| Prepro-Orexin (Human) |
A |
S |
V |
A |
P |
G |
G |
Q |
S |
G |
I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Prepro-Orexin (Rat) |
T |
A |
L |
A |
P |
R |
G |
G |
S |
R |
V |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Prepro-Orexin (Mouse) |
T |
A |
L |
A |
P |
R |
G |
G |
S |
G |
V |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Prepro-Hypocretin (Mouse)
sequence is identical to the Prepro-Orexin (Mouse) sequence. |
|
|
Structure Comparison of the Orexins with
the Hypocretins
Difference in Hypocretin-1 (Hyp-1) and Orexin-A.
The amino acid sequence of Hyp-1 is identical to that of Orexin-A
except Hyp-1 has 5 additional amino acids at the N-terminal (Leu-Gly-Val-Asp-Ala).
Both are amidated at the C-terminal.
Difference in Hypocretin-2 (Hyp-2) and Orexin-B.
The amino acid sequence of Hyp-2 is identical to that of Orexin-B,
including an amidated at the C-terminal.
Sakurai, T. et al. Cell 92, 573-585 (1998)
De Lecea, L., et al., PNAS 95, 322-327 (1998)
- Nishino, S. et al. Hypocretin (Orexin) deficiency in human narcolepsy.
Lancet, 355, 39-40 (2000)
- Lin, L. et al. The sleep disorder canine narcolepsy is caused
by a mutation in the hypocretin (orexin) receptor 2 gene. Cell,
98, 365-376 (1999)
- Chemelli, R.M., et al/ Narcolepsy in Orexin knock out mice:
molecular genetics of sleep regulation. Cell 98, 437-451 (1999)
- De Lecea, L. et al. The Hypocretins hypothalamous-specific peptides
with neuroexcitatory activity. Proc. Nat. Acad. Sci. 95, 322-327
(1998)
- Hagan, J.J. et al. Orexin A activates locus coeruleus cell firing
and increases arousal in the rat. Proc. Nat. Acad. Sci. 96, 10911-10916
(1999)
- Siegel, J.M. Narcolepsy, a key role for Hypocretins (Orexins).
Cell 98, 409-412 (1999)
- Samson, W.K., Gosnell, B., Chang, J.K., et al. Cardiovascular
regulatory actions of the Hypocretins in brain. Brain Res. 831,
241-253 (1999)
- Kirchgessner, A.L. and Liu, M. Orexin synthesis and response
in the gut. Neuron 1999 Dec. 24 (4): 941-51
- Lopez, M. et al. Orexin receptors are expressed in the adrenal
medulla of the rat. Endocrinology 140, 5991-4 (1999)
- Yamamoto, Y. et al. Orexin receptors are expressed in the adreanal
medulla of the rat. Brain Res Mol Brain Res. 65, 14-22 (1999)
- Antonarakis, S.E. and Mckusick V.A. OMIM *602393 Hypocretin
Receptor
- Arihara Z, Takahashi K, Murakami O, Totsune K, Sone M, Satoh
F, Ito S, Hayashi Y, Sasano H, Mouri T. Orexin-A in the human
brain and tumor tissues of ganglioneuroblastoma and neuroblastoma.
Peptides 2000 Apr;21(4):565-70 Second Department of Internal Medicine,
Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku,
980-8574, Sendai, Miyagi, Japan. Orexin-A-like immunoreactivity
was detected in every region of human brain, but not in the pituitary.
The highest concentration of orexin-A-like immunoreactivity in
the human brain was found in hypothalamus (17.8 +/- 4.3 pmol/g
wet weight, mean +/- SEM, n = 7), followed by thalamus, medulla
oblongata, and pons. Orexin-A-like immunoreactivity was detected
in the tumor tissues of ganglioneuroblastoma and neuroblastoma,
but not in the tumor tissues of pheochromocytoma. Reverse phase
high performance liquid chromatographic analyses of the orexin-A-like
immunoreactivity in the human brain extracts and neuroblastoma
extracts showed a single immunoreactive peak, which was eluted
in an identical position to synthetic human orexin-A.
|
|